- Home
- VRCA vs MAIA Comparison
VRCA vs MAIA Comparison
Compare VRCA & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- MAIA
- Stock Information
- Founded
- VRCA 2013
- MAIA 2018
- Country
- VRCA United States
- MAIA United States
- Employees
- VRCA N/A
- MAIA N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- VRCA Health Care
- MAIA Health Care
- Exchange
- VRCA Nasdaq
- MAIA Nasdaq
- Market Cap
- VRCA 54.0M
- MAIA 46.7M
- IPO Year
- VRCA 2018
- MAIA 2022
- Fundamental
- Price
- VRCA $0.82
- MAIA $2.00
- Analyst Decision
- VRCA Hold
- MAIA
- Analyst Count
- VRCA 5
- MAIA 0
- Target Price
- VRCA $6.00
- MAIA N/A
- AVG Volume (30 Days)
- VRCA 745.9K
- MAIA 501.8K
- Earning Date
- VRCA 08-13-2025
- MAIA 08-08-2025
- Dividend Yield
- VRCA N/A
- MAIA N/A
- EPS Growth
- VRCA N/A
- MAIA N/A
- EPS
- VRCA N/A
- MAIA N/A
- Revenue
- VRCA $7,179,000.00
- MAIA N/A
- Revenue This Year
- VRCA $171.87
- MAIA N/A
- Revenue Next Year
- VRCA $71.38
- MAIA N/A
- P/E Ratio
- VRCA N/A
- MAIA N/A
- Revenue Growth
- VRCA N/A
- MAIA N/A
- 52 Week Low
- VRCA $0.38
- MAIA $1.40
- 52 Week High
- VRCA $8.98
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- VRCA 68.47
- MAIA 61.70
- Support Level
- VRCA $0.52
- MAIA $1.80
- Resistance Level
- VRCA $0.67
- MAIA $2.03
- Average True Range (ATR)
- VRCA 0.08
- MAIA 0.13
- MACD
- VRCA 0.03
- MAIA 0.02
- Stochastic Oscillator
- VRCA 70.47
- MAIA 72.73
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.